Cargando…

Inhibition of CYR61-S100A4 Axis Limits Breast Cancer Invasion

Background and Objective: Matricellular proteins modulate the micro environment of tumors and are recognized to contribute to tumor cell invasion and dissemination. The cysteine-rich angiogenic inducer 61 (CYR61) is upregulated in mesenchymal transformed and invasive breast cancer cells. CYR61 corre...

Descripción completa

Detalles Bibliográficos
Autores principales: Hellinger, Johanna W., Hüchel, Silke, Goetz, Lena, Bauerschmitz, Gerd, Emons, Günter, Gründker, Carsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6819319/
https://www.ncbi.nlm.nih.gov/pubmed/31709177
http://dx.doi.org/10.3389/fonc.2019.01074
_version_ 1783463700497170432
author Hellinger, Johanna W.
Hüchel, Silke
Goetz, Lena
Bauerschmitz, Gerd
Emons, Günter
Gründker, Carsten
author_facet Hellinger, Johanna W.
Hüchel, Silke
Goetz, Lena
Bauerschmitz, Gerd
Emons, Günter
Gründker, Carsten
author_sort Hellinger, Johanna W.
collection PubMed
description Background and Objective: Matricellular proteins modulate the micro environment of tumors and are recognized to contribute to tumor cell invasion and dissemination. The cysteine-rich angiogenic inducer 61 (CYR61) is upregulated in mesenchymal transformed and invasive breast cancer cells. CYR61 correlates with poor prognosis of breast cancer patients. The signaling mechanism that causes invasive properties of cancer cells regarding to epithelial-mesenchymal transition (EMT) needs further research. In this study, we investigated the signaling mechanism, which is responsible for reduced cell invasion after suppression of CYR61 in mesenchymal transformed breast cancer cells and in triple negative breast cancer cells. Methods: We addressed this issue by generating a mesenchymal transformed breast cancer cell line using prolonged mammosphere cultivation. Western blotting and quantitative PCR were used to analyze gene expression alterations. Transient gene silencing was conducted using RNA interference. Proliferation was assessed using AlamarBlue assay. Invasiveness was analyzed using 2D and 3D invasion assays. Immune-histochemical analysis of patient tissue samples was performed to examine the prognostic value of CYR61 expression. Results: In this study, we investigated whether CYR61 could be used as therapeutic target and prognostic marker for invasive breast cancer. We discovered an interaction of CYR61 with metastasis-associated protein S100A4. Suppression of CYR61 by RNA interference reduced the expression of S100A4 dependent on ERK1/2 activity regulation. Non-invasive breast cancer cells became invasive due to extracellular CYR61 supplement. Immune-histochemical analysis of 239 patient tissue samples revealed a correlation of higher CYR61 and S100A4 expression with invasive breast cancer and metastasis. Conclusion: Our data suggest that suppression of CYR61 impedes the formation of an invasive cancer cell phenotype by reducing ERK1/2 phosphorylation thereby suppressing S100A4. These findings identify mechanisms by which CYR61 suppresses cell invasion and suggest it to be a potential therapeutic target and prognostic marker for invasive breast cancer and metastasis.
format Online
Article
Text
id pubmed-6819319
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-68193192019-11-08 Inhibition of CYR61-S100A4 Axis Limits Breast Cancer Invasion Hellinger, Johanna W. Hüchel, Silke Goetz, Lena Bauerschmitz, Gerd Emons, Günter Gründker, Carsten Front Oncol Oncology Background and Objective: Matricellular proteins modulate the micro environment of tumors and are recognized to contribute to tumor cell invasion and dissemination. The cysteine-rich angiogenic inducer 61 (CYR61) is upregulated in mesenchymal transformed and invasive breast cancer cells. CYR61 correlates with poor prognosis of breast cancer patients. The signaling mechanism that causes invasive properties of cancer cells regarding to epithelial-mesenchymal transition (EMT) needs further research. In this study, we investigated the signaling mechanism, which is responsible for reduced cell invasion after suppression of CYR61 in mesenchymal transformed breast cancer cells and in triple negative breast cancer cells. Methods: We addressed this issue by generating a mesenchymal transformed breast cancer cell line using prolonged mammosphere cultivation. Western blotting and quantitative PCR were used to analyze gene expression alterations. Transient gene silencing was conducted using RNA interference. Proliferation was assessed using AlamarBlue assay. Invasiveness was analyzed using 2D and 3D invasion assays. Immune-histochemical analysis of patient tissue samples was performed to examine the prognostic value of CYR61 expression. Results: In this study, we investigated whether CYR61 could be used as therapeutic target and prognostic marker for invasive breast cancer. We discovered an interaction of CYR61 with metastasis-associated protein S100A4. Suppression of CYR61 by RNA interference reduced the expression of S100A4 dependent on ERK1/2 activity regulation. Non-invasive breast cancer cells became invasive due to extracellular CYR61 supplement. Immune-histochemical analysis of 239 patient tissue samples revealed a correlation of higher CYR61 and S100A4 expression with invasive breast cancer and metastasis. Conclusion: Our data suggest that suppression of CYR61 impedes the formation of an invasive cancer cell phenotype by reducing ERK1/2 phosphorylation thereby suppressing S100A4. These findings identify mechanisms by which CYR61 suppresses cell invasion and suggest it to be a potential therapeutic target and prognostic marker for invasive breast cancer and metastasis. Frontiers Media S.A. 2019-10-23 /pmc/articles/PMC6819319/ /pubmed/31709177 http://dx.doi.org/10.3389/fonc.2019.01074 Text en Copyright © 2019 Hellinger, Hüchel, Goetz, Bauerschmitz, Emons and Gründker. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Hellinger, Johanna W.
Hüchel, Silke
Goetz, Lena
Bauerschmitz, Gerd
Emons, Günter
Gründker, Carsten
Inhibition of CYR61-S100A4 Axis Limits Breast Cancer Invasion
title Inhibition of CYR61-S100A4 Axis Limits Breast Cancer Invasion
title_full Inhibition of CYR61-S100A4 Axis Limits Breast Cancer Invasion
title_fullStr Inhibition of CYR61-S100A4 Axis Limits Breast Cancer Invasion
title_full_unstemmed Inhibition of CYR61-S100A4 Axis Limits Breast Cancer Invasion
title_short Inhibition of CYR61-S100A4 Axis Limits Breast Cancer Invasion
title_sort inhibition of cyr61-s100a4 axis limits breast cancer invasion
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6819319/
https://www.ncbi.nlm.nih.gov/pubmed/31709177
http://dx.doi.org/10.3389/fonc.2019.01074
work_keys_str_mv AT hellingerjohannaw inhibitionofcyr61s100a4axislimitsbreastcancerinvasion
AT huchelsilke inhibitionofcyr61s100a4axislimitsbreastcancerinvasion
AT goetzlena inhibitionofcyr61s100a4axislimitsbreastcancerinvasion
AT bauerschmitzgerd inhibitionofcyr61s100a4axislimitsbreastcancerinvasion
AT emonsgunter inhibitionofcyr61s100a4axislimitsbreastcancerinvasion
AT grundkercarsten inhibitionofcyr61s100a4axislimitsbreastcancerinvasion